Psychedelics

Sa'ed Al-Olimat, PharmD, also discussed the potentially groundbreaking shift for MDMA expected later in 2024.

LSD d-tartrate (MM-120) showed rapid improvements in patients with generalized anxiety disorder by day 2 of the study.

At 4 months, 75% of participants achieved remission and no longer showed signs of depression symptoms in a phase 2 clinical trial.

If clinical trials continue to show that psychedelics offer safe and long-lasting results, then psychedelic-assisted therapy could flourish as a treatment in the mental health space.

Many psychedelics being studied for clinical use are not "magic mushrooms", rather clinical drugs formulated using good manufacturing practice standards.

Investigators continue to conduct regulated and controlled clinical trials to build compelling, high-quality evidence on their therapeutic potential.

If approved, this would mark the first MDMA-assisted therapy and psychedelic-assisted therapy approved, calling for a reschedule of MDMA from Schedule I. A PDUFA was set for this summer.

The co-founders of PPA discuss the importance of advocacy work at this point in the development of the psychedelic medicine industry to help cement pharmacist’s role in the continuum of care.

The investigators note that psilocybin’s effectiveness in treating depressive symptoms and the positive reception among patients with cancer are encouraging continued research.

By combining the administration of psychedelic compounds with therapeutic support, ketamine-assisted therapy is proving remarkable efficacy in treating mental health conditions.

Jordan Sloshower, MD, MSc, describes his experience working in several clinical trials investigating psilocybin-assisted therapy.

In the clinical setting, psychedelic medicine has promise as a safe and efficacious treatment for PTSD, TBIs, and other mental health issues.

Ketamine topical cream may alleviate symptoms of PTSD without causing the adverse effects and abuse potential often associated with other forms of ketamine administration.

California is possibly on the verge of signing a bill that would decriminalize the personal possession of natural psychedelics for those aged 21 years and older.

Although it has some daunting adverse effects, Glenn Short, PhD, said ibogaine offers unique biological and therapeutic effects.

KET01 could successfully treat treatment-resistant depression while limiting adverse effects in the home environment, according to the study.

The daily oral formulation of ketamine, KET01, has the potential to greatly improve the standard treatment practices for treatment-resistant depression, according to investigators.

Generic ketamine could cost as little as $5, which is significantly lower than the $800 per dose for the currently available S-ketamine nasal spray.

Quality standards and national regulation help to establish its role as medicine.

David Keene, vice president of Digital Therapeutics at atai Life Sciences, discussed the growth and future of digital therapeutics.

Further research and regulatory changes are needed, but psychedelic medicines may be able to treat or even cure mental illness in the future.

The use of psilocybin and psychedelic therapy can be a helpful tool for individuals with AUD and could have a positive outcome that can result in self compassion.

Renewed focus on the potential this drug can provide patients is upon us as we continue to strive for greater and better care and treatment for patients throughout US health systems.

This month, we have a special crossover episode between Pharmacy Focus: Oncology Edition and the Psychedelic Pharmacy podcast.

Providing this treatment for patients with cancer may be a smoother transition for oncology professionals than they might expect.